News
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...
Eli Lilly (NYSE:LLY) said Thursday that Ilya Yuffa, executive vice president and president, Lilly International, will become ...
Emmy and Golden Globe-winning actress Patricia Clarkson joins Morning Joe to discuss starring as equal pay-activist Lilly ...
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
Eli Lilly has broken ground on a massive new research facility in Lebanon that will support hundreds of jobs and focus on ...
Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...
Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs now tops 50%. Notably, Lilly's market share is increasing while Novo ...
Lilly Ledbetter is an icon in the fight for equal pay. Ledbetter was a manager at the Goodyear Tire & Rubber Co. plant in Gadsden. Once she learned she was earning less than her male colleagues – she ...
Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an ...
The new research and development site will combine research, process development and clinical trial manufacturing ...
Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results